Drug intelligence / Profile preview

ST-7775

Development stage: Preclinical
Lead developer: Beijing Scitech-Mq Pharmaceuticals
Modality: Small Molecules

Overview

ST-7775 is a small molecule therapeutic candidate being developed by Beijing Scitech-Mq Pharmaceuticals. Currently in the preclinical stage of development, it is being investigated for its potential in treating a range of conditions, including neurodegeneration, nerve injury, depression, and frailty. While the specific biological target and mechanism of action remain undisclosed by the developer, the drug's broad focus on both neurological repair and systemic conditions like frailty suggests a potential role in neuroprotection or regenerative medicine.

Beyond the preview

Go deeper on ST-7775.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST-7775.

Explore the full profile